LL-37 5mg (CAP-18)

LL-37 5mg (CAP-18 fragment) is a synthetic antimicrobial peptide studied in controlled laboratory environments for its interaction with innate immune signaling pathways and cellular defense mechanisms. In experimental biological systems, LL-37 5mg is evaluated for membrane-interaction dynamics, receptor-associated signaling modulation, and intracellular communication pathways within defined research frameworks.

LL-37 is derived from the human cathelicidin antimicrobial peptide (hCAP-18) and represents the active C-terminal peptide fragment studied in molecular and cellular research. Scientific investigations focus on how LL-37 5mg interacts with cellular membranes, toll-like receptor (TLR) pathways, cytokine-associated signaling cascades, and transcriptional regulatory mechanisms under controlled in vitro and in vivo experimental conditions.

Research Overview

LL-37 5mg has been examined in preclinical research exploring innate immune signaling models and peptide-mediated intracellular regulatory frameworks. Scientific interest centers on how LL-37 interacts with pathogen-associated molecular patterns (PAMPs), modulates inflammatory signaling cascades, and influences transcriptional response pathways within defined laboratory systems.

Experimental investigations evaluate molecular markers associated with toll-like receptor modulation, NF-κB pathway activity, cytokine-associated signaling responses, and membrane-binding dynamics when studying LL-37 5mg in controlled research environments.

Research frameworks emphasize molecular stability, structural reproducibility, and pathway-specific characterization across validated biological models.

Mechanism of Study

The mechanism of study for LL-37 5mg involves evaluation of membrane-associated interactions and intracellular immune signaling modulation in experimental systems.

Investigators analyze:

• Membrane-binding affinity
• Toll-like receptor (TLR) pathway modulation
• NF-κB signaling markers
• Cytokine-associated transcriptional responses
• Intracellular kinase activation cascades

Laboratory systems assess how LL-37 5mg influences cellular defense signaling frameworks and downstream molecular communication pathways under defined research protocols. These investigations are conducted strictly for laboratory research purposes.

Structural Characteristics

LL-37 5mg is classified as a synthetic 37–amino acid peptide corresponding to the active fragment of hCAP-18. Analytical studies focus on molecular weight confirmation, peptide sequence integrity, and chromatographic purity validation to ensure research-grade consistency.

Laboratory characterization frequently includes evaluation of structural stability, membrane-interaction modeling, and analytical verification of molecular composition across validated assays.

Applications in Research

LL-37 5mg is utilized in experimental systems investigating innate immune signaling pathways, antimicrobial peptide interactions, and intracellular inflammatory regulatory models.

Research protocols frequently assess:

• Membrane interaction dynamics
• Cytokine-associated signaling modulation
• Intracellular transcription factor activation
• Structural reproducibility across assays

Analytical frameworks emphasize molecular integrity, purity verification, and consistent batch-to-batch performance within defined laboratory environments.

Product Specifications

• 5mg per vial
• Synthetic LL-37 peptide (CAP-18 fragment)
• Lyophilized powder for enhanced stability
• ≥99% HPLC verified purity
• Third-party tested
• Research use only
• Store at -20°C

LL-37 5mg is supplied in lyophilized form to preserve molecular integrity during storage and transit. Proper laboratory handling procedures are recommended to maintain peptide stability prior to experimental preparation.

Certificate of Analysis

Each batch of LL-37 5mg undergoes independent analytical verification to confirm purity and structural identity. High-Performance Liquid Chromatography (HPLC) testing confirms ≥99% purity prior to release for research distribution.

Additional analytical characterization methods may include mass spectrometry and peptide mapping procedures to validate molecular structure and batch-to-batch consistency. Certificates of Analysis may be available upon request.

Laboratory Handling & Storage

LL-37 5mg should be stored at -20°C in a temperature-controlled laboratory environment prior to reconstitution. Lyophilized peptide compounds are formulated to maintain stability when handled according to validated laboratory standards.

Upon preparation for experimental procedures, researchers typically follow established laboratory protocols to preserve structural integrity and ensure reliable analytical outcomes.

Frequently Asked Questions

Q: Is LL-37 5mg intended for human consumption?
A: No. This compound is strictly intended for laboratory research use only.

Q: What does CAP-18 refer to?
A: CAP-18 is the precursor protein from which the LL-37 peptide fragment is derived in research contexts.

Q: How is purity verified?
A: Purity is confirmed through validated High-Performance Liquid Chromatography (HPLC) testing procedures.

For research use only. Not for human consumption.